Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial.
Saved in:
| Title: | Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial. |
|---|---|
| Authors: | Kristensen, Lars Erik1 (AUTHOR) lars.erik.kristensen@regionh.dk, Keiserman, Mauro2 (AUTHOR), Papp, Kim3,4 (AUTHOR), McCasland, Leslie5 (AUTHOR), White, Douglas6,7 (AUTHOR), Carter, Kyle8 (AUTHOR), Lippe, Ralph8 (AUTHOR), Photowala, Huzefa8 (AUTHOR), Drogaris, Leonidas8 (AUTHOR), Soliman, Ahmed M.8 (AUTHOR), Chen, Michael8 (AUTHOR), Padilla, Byron8 (AUTHOR), Behrens, Frank9 (AUTHOR) |
| Source: | Rheumatology & Therapy. Jun2024, Vol. 11 Issue 3, p617-632. 16p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
